International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children With an Underlying Oncologic Diagnosis.

OBJECTIVES To describe the epidemiology of platelet transfusions in critically ill children with an underlying oncologic diagnosis and to examine effects of prophylactic versus therapeutic transfusions. DESIGN Subgroup analysis of a prospective, observational study. SETTING Eighty-two PICUs in 16 countries. PATIENTS All children (3 d to 16 yr old) who received a platelet transfusion during one of the six predefined screening weeks and had received chemotherapy in the previous 6 months or had undergone hematopoietic stem cell transplantation in the last year. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS Of the 548 patients enrolled in the parent study, 237 (43%) had an underlying oncologic diagnosis. In this population, 71% (168/237) of transfusions were given prophylactically, and 59% (139/237) of transfusions were given at a total platelet count greater than 20 × 10/L, higher than the current recommendations. Those with an underlying oncologic diagnosis were significantly older, and received less support including less mechanical ventilation, fewer medications that affect platelet function, and less use of extracorporeal life support than those without an underlying oncologic diagnosis. In this subpopulation, there were no statistically significant differences in median (interquartile range) platelet transfusion thresholds when comparing bleeding or nonbleeding patients (50 × 10/L [10-50 × 10/L] and 30 × 10/L [10-50 × 10/L], respectively [p = 0.166]). The median (interquartile range) interval transfusion increment in children with an underlying oncologic diagnosis was 17 × 10/L (6-52 × 10/L). The presence of an underlying oncologic diagnosis was associated with a poor platelet increment response to platelet transfusion in this cohort (adjusted odds ratio, 0.46; 95% CI, 0.22-0.95; p = 0.035). CONCLUSIONS Children with an underlying oncologic diagnosis receive nearly half of platelet transfusions prescribed by pediatric intensivists. Over half of these transfusions are prescribed at total platelet count greater than current recommendations. Studies must be done to clarify appropriate indications for platelet transfusions in this vulnerable population.

[1]  E. Deconinck,et al.  Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study , 2018, Transfusion.

[2]  P. Rebulla,et al.  Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Maurer-Spurej,et al.  Microparticle detection to guide platelet management for the reduction of platelet refractoriness in children - A study proposal. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[4]  S. Stanworth,et al.  Guidelines on transfusion for fetuses, neonates and older children , 2016, British journal of haematology.

[5]  J. Zimring,et al.  Metabolites in stored platelets associated with platelet recoveries and survivals , 2016, Transfusion.

[6]  J. Chiche,et al.  Platelet transfusions in cancer patients with hypoproliferative thrombocytopenia in the intensive care unit , 2015, Annals of Intensive Care.

[7]  Bruno Grandbastien,et al.  PELOD-2: An Update of the PEdiatric Logistic Organ Dysfunction Score , 2013, Critical care medicine.

[8]  B. Souweine,et al.  Epidemiology and outcome of thrombocytopenic patients in the intensive care unit: results of a prospective multicenter study , 2013, Intensive Care Medicine.

[9]  E. Wood,et al.  A no-prophylaxis platelet-transfusion strategy for hematologic cancers. , 2013, The New England journal of medicine.

[10]  B. Souweine,et al.  Management of thrombocytopenia in the ICU (pregnancy excluded) , 2012, Annals of Intensive Care.

[11]  S. Assmann,et al.  Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. , 2012, Blood.

[12]  François Vincent,et al.  Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. , 2007, Chest.

[13]  C. Koebnick,et al.  Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome* , 2002, Critical care medicine.

[14]  J M Rainey,et al.  Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[16]  R. Strauss,et al.  Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Sepsis Investigators Platelet Transfusion Practices in Critically Ill Children , 2018 .

[18]  P. Rebulla,et al.  Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. , 2015, Transfusion medicine reviews.